Literature DB >> 12218292

Production of macrophage migration inhibitory factor by human and murine neuroblastoma.

Qian Bin1, Bryon D Johnson, Dennis W Schauer, James T Casper, Rimas J Orentas.   

Abstract

Tumor cells avoid immune recognition by subverting the ability of the immune system to mount an inflammatory response that generates cytotoxic effector cells. This can be achieved through cytokine production by the tumor itself. Our objective was to determine the cytokine profile of neuroblastoma (NB) lesions in tumor vaccine models. We found that the murine NB cell line, Neuro2a, secretes macrophage migration inhibitory factor, MIF, a multifunctional cytokine with the potential to block effective immune responses to a tumor. Patient-derived NB cell lines were also found to produce MIF. MIF production by NB was documented at the level of RNA by RNAse protection, soluble cytokine production by ELISA, and in a macrophage migration assay. Our studies also confirmed reports of IL-6 production by human NB cell lines. NB culture-derived MIF was also shown to activate tumor cell migration. This supports the hypothesis that MIF is a tumor-derived cytokine that may play a role in NB aggressiveness and evasion of immune recognition. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218292     DOI: 10.1159/000064028

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.

Authors:  Chia-Tung Shun; Jaw-Town Lin; Shih-Pei Huang; Min-Tsan Lin; Ming-Shiang Wu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

Review 2.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

3.  Macrophage migration inhibitory factor stimulated by Helicobacter pylori increases proliferation of gastric epithelial cells.

Authors:  Harry Hua-Xiang Xia; Shiu Kum Lam; Annie O O Chan; Marie Chia Mi Lin; Hsiang Fu Kung; Keiji Ogura; Douglas E Berg; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

4.  Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.

Authors:  Kristen M Barr; Weiqing Jing; William H D Hallett; Jill A Gershan; Bryon D Johnson
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

5.  Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.

Authors:  Xiaocai Yan; Rimas J Orentas; Bryon D Johnson
Journal:  Cytokine       Date:  2006-03-07       Impact factor: 3.861

6.  Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo.

Authors:  Qiang Zhou; Xiaocai Yan; Jill Gershan; Rimas J Orentas; Bryon D Johnson
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

Review 7.  Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.

Authors:  Cristina Bottino; Alessandra Dondero; Francesca Bellora; Lorenzo Moretta; Franco Locatelli; Vito Pistoia; Alessandro Moretta; Roberta Castriconi
Journal:  Front Immunol       Date:  2014-02-12       Impact factor: 7.561

Review 8.  Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

Authors:  Eugenio Cavalli; Rosella Ciurleo; Maria Cristina Petralia; Paolo Fagone; Rita Bella; Katia Mangano; Ferdinando Nicoletti; Placido Bramanti; Maria Sofia Basile
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.